A crucial development for American patients this year is the Fourth Temporary Extension of telemedicine flexibilities. On January 2, 2026, the Drug Enforcement Administration (DEA) and the Department of Health and Human Services (HHS) announced that the ability for registered practitioners to prescribe Schedule II-V controlled substances via telehealth has been extended through December 31, 2026. This extension acts as a "bridge" to prevent a disruption in care, ensuring that patients can continue to receive treatment without the immediate necessity of an in-person visit.